Total revenue from operations rose 9.1 to Rs 4,369 crore, boosted by the strength in US formulation segment, which constitutes 44 of the business
Consolidated net profit fell to Rs 33.35 crore ($4.01 million) for the second quarter ended September 30, from Rs 58.76 crore a year ago
The company's revenue from operations during the quarter under review was seen at Rs 2,262.9 crore, down 16 per cent compared to Rs 2,680.8 crore during the same period in 2022-23
RR Kabel's consolidated revenue from operations rose almost 20% to Rs 1,610 crore, offsetting a nearly 15% climb in total expenses, led by a spike in raw material costs
The price freeze led to the three firms incurring losses in the first half of 2022-23 fiscal year (April 2022 to March 2023)
The company's consolidated revenue from operations, meanwhile, grew 22 per cent to Rs 1,507 crore, up from Rs 1,230.8 crore a year ago, and Rs 1,421.8 crore in Q1 FY24
Disbursements for H1 FY'24 recorded a growth of 34 per cent to Rs 13,430 crore as compared to Rs 10,054 crore registered in H1 FY'23
Its consolidated net profit was Rs 1,685.81 crore in the quarter ended September last year, a BSE filing showed
Its asset under management (AUM) grew by 25 per cent to Rs 10,026 crore compared to Rs 8,047 at the end of September 2022
Quarterly revenue was up 39% at Rs 1,104 crore, however, a 44% rise in its total expenses, in line with the trend seen in the previous three quarters, weighed on profit
Revenue from operations in the September quarter was Rs 549.43 crore. It was at Rs 506.16 crore in the corresponding quarter, it said
Analysts, however, flagged muted launches by regional developers, including Sobha peers Prestige Estate Projects and Brigade Enterprises
International patient revenue also grew by 25 per cent Y-o-Y
HeidelbergCement India's total expenses in the September quarter were at Rs 532.47 crore, up 4.96 per cent
The rise in consolidated revenue, the company said, was on account of newly commissioned transmission lines and other related commissioning
During the second quarter, in the automotive division, demand started to pick up both with OEMs
Gland Pharma reported a nearly 32% jump in revenue from operations to Rs 1,373 crore, driven by higher sales from the acquisition of the French pharmaceutical group Cenexi in January
EBITDA stood at Rs 77.8 crore, declining 6.2 per cent year-on-year and growing 16.1 per cent sequentially
The total income for Q2FY24 came in at Rs 3,766.46 crore, compared to Rs 3,376.57 crore year-on-year
The company said all hospitals improved their average revenue per operating bed (ARPOB) during the period and the overall average growth in ARPOB stood at 13 per cent year-on-year (YoY)